People: IGI Laboratories Inc (IG)
IG on American Stock Exchange
1.67USD
17 May 2013
1.67USD
17 May 2013
Price Change (% chg)
$-0.09 (-5.11%)
$-0.09 (-5.11%)
Prev Close
$1.76
$1.76
Open
$1.71
$1.71
Day's High
$1.71
$1.71
Day's Low
$1.60
$1.60
Volume
29,871
29,871
Avg. Vol
59,378
59,378
52-wk High
$2.25
$2.25
52-wk Low
$0.94
$0.94
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Joyce Erony |
52 | 2011 | Independent Chairwoman of the Board |
Jason Grenfell-Gardner |
37 | 2012 | President, Chief Executive Officer, Director |
Jenniffer Collins |
43 | 2011 | Chief Financial Officer |
Nadya Lawrence |
43 | 2010 | Executive Vice President - Sales and Marketing |
Narendra Borkar |
71 | 2009 | Independent Director |
Bhaskar Chaudhuri |
57 | 2010 | Independent Director |
James Gale |
63 | 2009 | Independent Director |
Michael Hemric |
59 | 2009 | Independent Director |
Georgia Giannikopoulos |
Customer Relations Representative |
Biographies
| Name | Description |
|---|---|
Joyce Erony |
Ms. Joyce Erony is Independent Chairwoman of the Board of IGI Laboratories, Inc. She Managing Director of Signet Healthcare Partners. Prior to joining Signet, Ms. Erony spent 14 years (1991-2004) at Salomon Brothers Inc., Salomon Smith Barney, Inc. and ultimately Citigroup, which acquired the former companies, most recently as Managing Director responsible for Citigroup’s activities in Specialty Pharmaceuticals. Prior to joining Citigroup, Ms. Erony worked as an economist (1983-1991), primarily at the World Bank and International Finance Corporation advising various international development agencies and multilateral organizations. From January 2011 through July 2011, Ms. Erony served as the interim Chief Financial Officer while the Company conducted a search for a permanent replacement. Ms. Erony has served as a director of Dow Pharmaceutical Sciences, Inc., Control Delivery Systems, Inc., Anteis, S.A., ORBIS International and Atlantis Components, Inc. Ms. Erony holds a Diploma in International Law and Economics from the London School of Economics and Political Science (1982) and a BS in Management from Case Western Reserve University (1981). |
Jason Grenfell-Gardner |
Mr. Jason Grenfell-Gardner is appointed as President, Chief Executive Officer, Director of IGI Laboratories, Inc. Since July 2008, Mr. Grenfell-Gardner, was the Senior Vice President of Sales and Marketing for West-Ward Pharmaceuticals Corp., the U.S. Subsidiary of Hikma Pharmaceuticals PLC, a generic pharmaceutical manufacturer. Prior to that, Mr. Grenfell-Gardner served as West-Ward Pharmaceuticals’s General Manager - Injectables, North America (December 2007 to July 2008) and its Director of Business Development (October 2006 to December 2007). Mr. Grenfell-Gardner joined West-Ward Pharmaceuticals in 2004 to lead its initial public offering. Prior to joining West-Ward Pharmaceuticals, Mr. Grenfell-Gardner was an investment banker with Trigon Capital. Prior to 2004, Jason gained a number of years of investment banking experience in Central and Eastern Europe with Trigon Capital, and served as Chairman of the Board of Sanitas Pharmaceuticals. Jason has an MA in Economics from the University of St. Andrews in Scotland, and an MBA from INSEAD, where he studied in both France and Singapore. |
Jenniffer Collins |
Ms. Jenniffer Collins is Chief Financial Officer of IGI Laboratories Inc., since July 21, 2011. Ms. Collins has twenty years of experience in accounting and finance. Prior to joining IGI, she most recently served from October 2006 to July 2011 as Vice President-Treasurer and previously the Corporate Controller at the Lightstone Group, a privately held real estate firm. From January 2004 through October 2006, Ms. Collins also served as Corporate Controller for Orchid Cellmark, Inc., a biotechnology company, and from July 2001 through January 2004 Ms. Collins served as Director of Finance and Investor Relations for Tellium, Inc. an optical switching company, which was purchased by Zhone Technologies, Inc in November 2003. Her background also includes seven years of public accounting experience, including a position with Pricewaterhouse Coopers. Jenniffer earned her CPA in New Jersey in 1993 and graduated with a B.S. in accounting from Lehigh University. |
Nadya Lawrence |
Ms. Nadya Lawrence is Executive Vice President - Sales and Marketing of IGI Laboratories Inc., since April 2010. From 2006 to April 2010, Ms. Lawrence served as the Executive Vice President of Operations and from 2001 to 2006 she served as the Vice President of Operations. Previously, Ms. Lawrence served as the R&D Technical Director and R&D Manager from 1995 to 2001. |
Narendra Borkar |
Mr. Narendra N. Borkar is an Independent Director of IGI Laboratories, Inc., since September 2009. Mr. Borkar has served as Chief Executive Officer of Aurobindo Pharma USA (2004-2006), Chief Executive Officer of Caraco Pharmaceutical Laboratories (1997- 2003), various senior roles for Novartis (formerly Ciba-Geigy) (1981-1997), General Manager of Apte Amalgamation (1979-1981), Works Engineer for Hoffman La Roche (1976-1979), Project Manager for Union Carbide Corp. and Merck & Company, Inc. (1966-1976). |
Bhaskar Chaudhuri |
Dr. Bhaskar Chaudhuri, Ph.D., is an Independent Director of IGI Laboratories, Inc., since December 2010. Mr. Chaudhuri has more than 20 years experience in pharmaceutical management, research and development. Mr. Chaudhuri served as President of Valeant Pharmaceuticals International until September 2010. Prior to joining Valeant, upon Valeant’s acquisition of Dow Pharmaceutical Sciences, Inc. in 2008, Mr. Chaudhuri served for seven years as Dow’s President and Chief Executive Officer and a member of Dow’s Board of Directors from 2003 to 2008. Prior to that, Mr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories. Prior to his positions at Bertek, Mr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan Laboratories. Mr. Chaudhuri joined Mylan through the acquisition of Penederm, Inc., where he worked from 1992 to 1998 in a number of senior positions before becoming the Vice President of R&D. Mr. Chaudhuri holds a Doctorate in Physical Pharmacy from the University of Louisiana, a Masters of Science in Industrial Pharmacy and a Bachelors of Science in Pharmacy from India. |
James Gale |
Mr. James C. Gale is an Independent Director of IGI Laboratories Inc., since May 2009. He is Founding Partner of Signet Healthcare Partners. Prior to founding Signet, Mr. Gale was head of principal investment activities and investment banking at Gruntal & Co., LLC. Prior to joining Gruntal, Mr. Gale originated and managed private equity investments for Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior Investment Banker at E.F. Hutton & Co. Mr. Gale is currently the Chairman of the Board of Alpex Pharma S.A. and also serves on the Board of Directors of Anteis SA, Octoplus BV, Pfenex Inc., Spepharm BV and Paladin Laboratories. Mr. Gale holds a Masters of Business Administration from the University of Chicago. |
Michael Hemric |
Mr. Michael B. Hemric is an Independent Director of IGI Laboratories, Inc., since July 1, 2009. Mr. Hemric was Executive with Alcon Laboratories (1980-2008), including Area President/Far East (2007-2008), Vice President/General Manager – Pharmaceutical Division (2002- 2006), Vice President/Area Manager for Southeast Asia (1999-2002), Vice President/General Manager - Consumer Products Division (1997- 1999). Earlier in his career, Mr. Hemric was involved in Sales at Alcon Laboratories and other companies, including The Gillette Company. |
Georgia Giannikopoulos |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Joyce Erony |
-- |
Jason Grenfell-Gardner |
-- |
Jenniffer Collins |
198,165 |
Nadya Lawrence |
186,632 |
Narendra Borkar |
-- |
Bhaskar Chaudhuri |
-- |
James Gale |
-- |
Michael Hemric |
-- |
Georgia Giannikopoulos |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Joyce Erony |
0 | 0 |
Jason Grenfell-Gardner |
0 | 0 |
Jenniffer Collins |
0 | 0 |
Nadya Lawrence |
285,205 | 20,100 |
Narendra Borkar |
0 | 0 |
Bhaskar Chaudhuri |
0 | 0 |
James Gale |
0 | 0 |
Michael Hemric |
0 | 0 |
Georgia Giannikopoulos |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
ERONY JOYCE |
5,000 | $1.33 |
GALE JAMES C |
10,000 | $1.33 |
ERONY JOYCE |
12,500 | $1.30 |
HEMRIC MICHAEL B |
2,100 | $1.34 |
HEMRIC MICHAEL B |
900 | $1.34 |
HEMRIC MICHAEL B |
3,000 | $1.21 |
HEMRIC MICHAEL B |
468 | $1.18 |
HEMRIC MICHAEL B |
1,532 | $1.18 |
HEMRIC MICHAEL B |
7,639 | $1.15 |
HEMRIC MICHAEL B |
4,998 | $1.14 |
GRENFELL GARDNER JASON |
10,000 | $1.15 |
COLLINS JENNIFFER L |
12,206 | $0.00 |
LAWRENCE NADYA |
7,000 | $0.95 |
LAWRENCE NADYA |
5,342 | $0.65 |
LAWRENCE NADYA |
7,000 | $0.65 |
LAWRENCE NADYA |
10,000 | $0.95 |
LAWRENCE NADYA |
10,000 | $0.65 |
LAWRENCE NADYA |
907 | $1.00 |
LAWRENCE NADYA |
907 | $0.65 |
LAWRENCE NADYA |
843 | $1.00 |
LAWRENCE NADYA |
843 | $0.65 |
LAWRENCE NADYA |
300 | $1.02 |
LAWRENCE NADYA |
300 | $0.65 |
LAWRENCE NADYA |
608 | $0.65 |
LAWRENCE NADYA |
608 | $1.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
